A Phase 1b Parallel Cohort Study Evaluating the Efficacy and Safety of Momelotinib and Momelotinib Combined With Trametinib in Subjects With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase

Trial Profile

A Phase 1b Parallel Cohort Study Evaluating the Efficacy and Safety of Momelotinib and Momelotinib Combined With Trametinib in Subjects With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase

Discontinued
Phase of Trial: Phase I

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Momelotinib (Primary) ; Trametinib
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 24 Mar 2017 Status changed from active, no longer recruiting to discontinued.
    • 04 Aug 2016 Planned End Date changed from 1 Mar 2017 to 1 Apr 2017.
    • 13 May 2016 Planned End Date changed from 1 Mar 2018 to 1 Mar 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top